Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 04, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically detailing activities within the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications and does not contain financial performance data.
Material Changes
The filing details specific share transactions executed by the SmithKline Beecham Employee Benefit Trust on behalf of plan participants:
- March 26, 2007: 2,427 shares sold at GBP 13.99 per share; 3,405 shares transferred to a participant in the Annual Investment Plan.
- March 27, 2007: 1,175 shares sold at GBP 13.75 per share; 2,534 shares transferred to participants in the Bonus Investment Plan.
- March 29, 2007: 1,884 shares sold at GBP 13.80 per share; 2,688 shares transferred to a participant in the Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J S Heslop holds an interest in the fund shares similarly to other beneficiaries.
Investor Verification Points
- Verify the total volume of shares sold versus transferred within the Employee Benefit Trust during the reporting period.
- Confirm the specific share prices (GBP 13.75 to GBP 13.99) against market data for late March 2007.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure all connected person transactions were properly reported.